Preoperative usages of levosimendan in patients undergoing coronary artery bypass grafting

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 1, 2014, Pages 219-229

  Eris, Cuneyt ^a   Yavuz, Senol ^a   Toktas, Faruk ^a   Turk, Tamer ^a   Gucu, Arif ^a   Erdolu, Burak ^a   Goncu, M Tugrul ^a  

^a BURSA YUKSEK IHTISAS TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Cardiac surgery; Levosimendan; Low cardiac output; Preoperative usage

Indexed keywords

EID: 84892564652     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Packer M. The search for the ideal positive inotropic agent. N Eng J Med 1993; 329: 201-202.
2. Shahzad GR and Benson SR. Levosimendan in cardiac surgery: current best available evidence. Ann Thorac Surg 2006; 81: 1536-1546.
3. De Hert SG, Lorsomradee S, Cromheecke S and Van der Linden PJ. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg 2007; 104: 766-773.
4. Antila S, Sundberg S and Lehtonen LA. Clinical pharmacology of levosimendan. Clin Pharmacokinet 2007; 46: 535-552.
5. Yokoshiki H, Katsube Y, Sunagawa M and Sperelakis N. Levosimendan, a novel Ca 2 sensitizer, activates the glibenclamide-sensitive K-channel in rat arterial myocytes. Eur J Pharmacol 1997; 333: 249-259.
6. Kaheinen P, Pollesello P, Levijoki J and Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 2001; 37: 367-374.
7. Harkin CP, Pagel PS, Tessmer JP and Warltier DC. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs. J Cardiovasc Pharmacol 1995; 26: 179-188.
8. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, Foster E and Chatterjee K. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress and myocardial oxygen uptake. Circulation 2005; 111: 1504-1509.
9. Grossini E, Molinari C, Caimmi PP, Uberti F and Vacca G. Levosimendan induces NO production through p38 MAPK. ERK and Akt in porcine coronary endothelial cells: role for mitochondrial K(ATP) channel. Br J Pharmacol 2009; 156: 250-261.
10. Yokoshiki H, Katsube Y, Sunagawa M and Sperelakis N. The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J Pharmacol Exp Ther 1997; 283: 375-383.
11. Waris KS, Ylinen RS and Harjola VP. Levosimendan in cardiac surgery. J Cardiothorac Vasc Anesth 2005; 19: 345-349.
12. Parissis JT, Andreadou I, Bistola V, Paraskevaidis I, Filippatos G and Kremastinos DT. Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert Opin Investig Drugs 2008; 17: 1143-1150.
13. Lehmann A, Boldt J, Lang J, Isgro F and Blome M. Is levosimendan an inoprotective drug in patients with acute coronary syndrome undergoing surgical revascularization? Anesthesiol Intensivmed Notfallmed Schmerzther 2003; 38: 577-582.
14. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T and Verani MS; American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105: 539-542.
15. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S and Salamon R; The EuroSCORE study group. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999; 16: 9-13.
16. Muller M, Junger A, Brau M, Kwapisz MM, Schindler E, Akinturk H, Benson M and Hempelmann G. Incidence and risk calculation of inotropic support in patients undergoing cardiac surgery with cardiopulmonary bypass using an automated anesthesia record-keeping system. Br J Anaesth 2002; 89: 398-404.
17. Ascione R, Narayan P, Rogers CA, Lim KH, Capoun R and Angelini GD. Early and midterm clinical outcome in patients with severe left ventricular dysfunction undergoing coronary artery surgery. Ann Thorac Surg 2003; 76: 793-799.
18. Butterworth JF 4th, Royster RL, Prielipp RC, Lawless ST and Wallenhaupt SL. Amrinone in cardiac surgical patients with left-ventricular dysfunction. A prospective, randomized placebo-controlled trial. Chest 1993; 104: 1660-1667.
19. Lobato EB, Florete O Jr and Bingham HL. A single dose of milrinone facilitates separation from cardiopulmonary bypass in patients with pre-existing left ventricular dysfunction. Br J Anaesth 1998; 81: 782-784.
20. Mentzer RM Jr, Oz MC, Sladen RN, Graeve AH, Hebeler RF Jr, Luber JM Jr, Smedira NG; NAPA Investigators. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery. The NAPA Trial. J Am Coll Cardiol 2007; 49: 716-726.
21. Kloner RA, Przyklenk K and Kay GL. Clinical evidence for stunned myocardium after coronary artery bypass surgery. J Card Surg 1994; 9: 397-402.
22. Khoynezhad A, Jalali Z and Tortolani AJ. Apoptosis; pathophysiology and therapeutic implications for the cardiac surgeon. Ann Thorac Surg 2004; 78: 1109-1118.
23. Wu X and Bers DM. Sarcoplasmic reticulum and nuclear envelope are one highly interconnected Ca2+ store throughout cardiac myocyte. Circ Res 2006; 99: 283-291.
24. Rajek AM, Koinig H, Jelen M, Schiferer A and Hutschala D. Levosimendan, a new Ca-sensitizer, in patients with poor left ventricular function undergoing cardiac surgery. Anesthesiol 2003; 99: A133.
25. Tritapepe L, De Santis V, Vitale D, Santulli M, Morelli A, Nofroni I, Puddu PE, Singer M and Pietropaoli P. Preconditioning effects of levosimendan in coronary artery bypass grafting-a pilot study. Br J Anaesth 2006; 96: 694-700.
26. Lorusso R, Gelsomino S, Carella R, Livi U, Mariscalco G, Onorati F, Russo C and Renzulli A. Impact of prophylactic intra-aortic balloon counter-pulsation on postoperative outcome in highrisk cardiac surgery patients: a multicentre, propensity-score analysis. Eur J Cardiothorac Surg 2010; 38: 585-591.
27. Meharwal ZS and Trehan N. Vascular complications of intra-aortic balloon insertion in patients undergoing coronary revascularization: analysis of 911 cases. Eur J Cardiothorac Surg 2002; 21: 741-747.
28. Bergh CH, Andersson B, Dahlström U, Forfang K, Kivikko M, Sarapohja T, Ullman B and Wikström G. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients in beta-blockers. Eur J Heart Fail 2010; 12: 404-410.
29. Kivikko M, Lehtonen L and Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003; 107: 81-86.
30. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP and Lehtonen L; Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe lowoutput heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196-202.
31. Adams JE 3rd, Bodor GS, Dávila-Román VG, Delmez JA, Apple FS, Ladenson JH and Jaffe AS. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation 1993; 88: 101-106.
32. Takeda S, Nakanishi K, Ikezaki H, Kim C, Sakamoto A, Tanaka K and Ogawa R. Cardiac marker responses to coronary artery bypass graft surgery with cardiopulmonary bypass and aortic cross-clamping. J Cardiothorac Vasc Anesth 2002; 16: 421-425.
33. Baggish AL, MacGillivray TE, Hoffman W, Newell JB, Lewandrowski KB, Lee-Lewandrowski E, Anwaruddin S, Siebert U and Januzzi JL. Postoperative troponin-T predicts prolonged intensive care unit length of stay following cardiac surgery. Crit Care Med 2004; 32: 1866-1871.
34. Aksun M, Karahan N, Adanir T, Aran G, Yetkin U, Oztürk T, Sencan A, Ozgürbüz U and Gürbüz A. Timing of levosimendan in cardiac surgery. Anadolu Kardiyol Derg 2009; 9: 223-230.
35. Pölönen P, Ruokonen E, Hippeläinen M, Pöyhönen M and Takala J. A prospective, randomized study of goal-oriented hemodynamic therapy in cardiac surgical patients. Anesth Analg 2000; 90: 1052-1059.
36. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, Nyquist O and Remme WJ. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1903-1912.
37. Lilleberg J, Sundberg S and Nieminen MS. Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 1995; 26 Suppl 1: S63-9.
38. Lilleberg J, Nieminen MS, Akkila J, Heikkilä L, Kuitunen A, Lehtonen L, Verkkala K, Mattila S and Salmenperä M. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998; 19: 660-668.
39. Singh BN, Lilleberg J, Sandell E, Ylonen V, Lehtonen L and Toivonen L. Effects of levosimendan on cardiac arrhythmia: electrophysiologic and ambulatory electrocardiographic findings in phase II and phase III clinical studies in cardiac failure. Am J Cardiol 1999; 83 Suppl 2: 16-20.
40. Mebazaa A and Erhardt L. Levosimendan: a new dual-action drug in the treatment of acute heart failure. Int J Clin Pract 2003; 57: 410-416.